A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
Latest Information Update: 23 Jan 2020
At a glance
- Drugs Pembrolizumab (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 16 Jan 2020 Planned End Date changed from 1 Apr 2023 to 1 Mar 2023.
- 16 Jan 2020 Planned primary completion date changed from 1 Apr 2021 to 1 Mar 2021.
- 16 Jan 2020 Status changed from not yet recruiting to recruiting.